Navigation Links
BioCis Pharma Starts Phase IIa Trial in Psoriasis
Date:3/12/2009

TURKU, Finland, March 12 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.

"With the commencement of this clinical trial we expand our clinical activities to a new dermatological indication," says Lasse Leino, CEO of BioCis Pharma. "Together with the ongoing phase IIa clinical trial in patients with mild to moderate atopic dermatitis, this first study in psoriasis will quickly enable us to obtain data to support our full-scale phase II clinical development program of ProtoCure(TM) emulsion cream in chronic skin inflammation. We expect to get results from both studies by third quarter of 2009."

Psoriasis is an immune-mediated chronic inflammatory disease characterized by local lesions on the skin. It affects about 2 to 3 per cent of the general population in the Western countries. Psoriasis may significantly impair the life quality of the affected subjects, and it may lead to psoriatic arthritis, an inflammatory disease affecting the joints. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd is an innovative drug development company with a business idea to develop drug therapies based on a novel, patented therapeutic principle. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Develo
'/>"/>

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
7. Pharmaxis Appoints French Distributor for Aridol(TM)
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 Reports from ... United States suffer from one or more chronic health ... cancer. Medication can address some of these diseases, but ... that many sufferers face. While implanted nerve stimulation devices ... the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... Houston, TX (PRWEB) December 17, 2014 ... marketing and administration for Stoller Group. In this position, ... Stoller Group, on administrative matters, develop marketing strategy and ... and services. , “Achim has tremendous knowledge and ... president of Stoller Group. “His experience and innovative thinking ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... May 8 BioLife Solutions Inc.,(OTC Bulletin Board: ... storage and cryopreservation media products for cells, tissues,and ... CryoStor,cryopreservation media has been accepted by the United ... and Chief Executive Mike Rice commented: "We believe,that ...
... May 7 Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) announced today that it ... the U.S.,financial markets open. Management will provide a Company update and,discuss the first ... Investors and other interested parties may access the call as follows:, ... Wednesday, May 14, ...
... and Company) (NYSE: BDX ), a global medical technology company,announced ... Bank of America 2008 Healthcare Conference ... Bernstein 24th Annual Strategic Decisions Conference 2008 ... A live webcast of BD,s presentations can be accessed from the ...
Cached Biology Technology:BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 2BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 3
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... the motion of the complete human rhinovirus, the most ... supercomputer, paving the way for new drug development. ... of all asthma exacerbations with more than 50 per ... per cent of patients with acute chronic obstructive pulmonary ...
... eventually cause anywhere from 15 to 1,300 deaths and ... Japan, Stanford researchers have calculated. The estimates have ... the radioactive release would likely cause no severe health ... roughly 600 deaths caused by the evacuation of the ...
... The University of Miami (UM) Rosenstiel School of Marine & ... Awards. The grantees were selected by a team of ... $11,000 in funds. , "We received 30 applications from every ... meteorology," said Laura Bracken Chaibongsai, Alumni & Outreach Manager for ...
Cached Biology News:3-D motion of cold virus offers hope for improved drugs using Australia's fastest supercomputer 2Stanford researchers calculate global health impacts of the Fukushima nuclear disaster 2Stanford researchers calculate global health impacts of the Fukushima nuclear disaster 3Recipients of UM Rosenstiel School's 2012-2013 Alumni Awards announced 2
... Degranulation, the secretion of cytoplasmic ... the inflammatory response of leukocytes (e.g. ... In addition to histamine, these secretory ... heparin, cytokines, chemokines, and many proteases ...
... things youll be telling others after you read ... Golemis, One look at the table of contents ... protein interaction will tell you immediately that this ... of your personal protein chemistry library. You will ...
... McCoy and his coworkers reported ... in vitro cultivation of Novikoff ... performed using,Basal Medium 5A and ... new medium known as McCoy's ...
Schneider's Drosophila - Insect medium...
Biology Products: